Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge (Nasdaq: BIOA) reported Phase 1 data for oral NLRP3 inhibitor BGE-102, showing rapid, large reductions in inflammatory biomarkers. In participants with obesity and elevated hsCRP, 60 mg QD (21 days) and 120 mg QD (14 days) produced median hsCRP reductions of ~85% and ~83–86%, respectively.
BGE-102 was well tolerated with no serious adverse events. BioAge plans a Phase 2 cardiovascular risk trial in H1 2026 with data expected H2 2026, and a Phase 1b/2a DME trial beginning mid-2026 with results anticipated mid-2027.
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
BioArctic (Nasdaq: B) announces the Nomination Committee's proposals for the Annual General Meeting on May 28, 2026. The committee proposes an eight-member board, re-electing Eugen Steiner as chair and six existing members, and adding Philip Scheltens and Linda Nilsson as new board members.
Pär Gellerfors has declined re-election; Linda Nilsson is proposed to represent the Gellerfors family's holding company. The Nomination Committee members represent ~57% of shares and ~83% of votes.
BioAge (NASDAQ: BIOA) reported full-year 2025 results and Q4 updates on March 24, 2026. Key clinical highlights include positive interim Phase 1 data for oral NLRP3 inhibitor BGE-102 with an 86% median hsCRP reduction at 120 mg and planned Phase 2a initiation in 1H 2026. The company completed an upsized follow-on offering raising $132.3 million and held $285.1 million in cash and marketable securities as of December 31, 2025, estimating funding through 2029.
BioArctic (NASDAQ: B) reported new data presented at AD/PD 2026 on long-term, real-world IV lecanemab treatment persistence and additional company presentations. Real-world claims analysis showed 78.4% persistence at 18 months, 71.7% at 20 months and 67.3% at 24 months. BioArctic also presented data on lecanemab binding to soluble Aβ protofibrils and a poster on exidavnemab trial screening using alpha-synuclein SAA. The release notes investigational status and no guarantee of regulatory approval.
BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.
Contact details for investor relations are provided for further inquiries.
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.
BioAge (Nasdaq: BIOA) priced an upsized underwritten public offering of 5,897,435 shares at $19.50 per share, producing gross proceeds of approximately $115.0 million. The offering is expected to close on or about January 23, 2026, subject to customary closing conditions. BioAge granted underwriters a 30-day option to purchase up to 884,615 additional shares. All shares are being offered by BioAge; proceeds are intended to fund research, clinical and process development and manufacturing (including BGE-102 and NLRP3 and APJ programs), working capital, capex, reduction of indebtedness and general corporate purposes.
Goldman Sachs, Piper Sandler and Citigroup are joint book-running managers; the offering is made under a Form S-3 registration that became effective November 25, 2025.